Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04956640
Title Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company

Advanced Solid Tumor


LY3214996 + LY3537982

LY3537982 + Sintilimab

Erlotinib + LY3537982

Abemaciclib + LY3537982


Cetuximab + LY3537982

LY3295668 + LY3537982

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.